Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

Impact · against what's priced in

The dermatology data updates are marginally positive as they expand the potential addressable market for EBGLYSS and explore synergies between GLP-1s and immunology, but they do not shift the fundamental valuation driver. The stock's current trajectory depends on GLP-1 revenue growth and production scaling rather than incremental pipeline expansions in dermatology.

LLY+0.10

Challenges what's priced in